NextGen Sciences, Berg Diagnostics
Neal Siegel, Glenn Barney, Hiroshi Saito, Jay Moyes, Michael Marletta, Richard Lerner
In about a month, the company plans to offer four assays targeted to neurodegenerative disease and heart disease, its CEO said.
The assays will be used by the drug company for preclinical and clinical studies.
Thermo Fisher's BRIMS Center is collaborating with NextGen Sciences to improve that company's suite of biomarker services.
The sale, for undisclosed cash and royalties, completes NextGen's realignment toward biomarker services.
Russian CRISPR researcher moves along with plans to ultimately alter the genes of embryos of deaf couples, though awaits regulatory approval, Nature News reports.
University of California, San Francisco, researchers have uncovered a gene mutations that appears to make a father-son duo more efficient sleepers.
NPR reports a large health insurer has begun to cover some pharmacogenetic tests for psychiatric drugs.
In PLOS this week: genome-wide association study of non-syndromic orofacial cleft subtypes, epigenetic and transcriptomic analysis of pancreatic ductal adenocarcinoma, and more.